A Fully Covered Irradiation Stent for the Palliation of Malignant Dysphagia

Malignant Dysphagia Clinical Trial

Official title:

A Novel Fully Covered Segmented Irradiation Stent Loaded With 125I Seeds for the Palliation of Malignant Dysphagia：a Prospective Pilot Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03186014
• Other study ID #: 2017ZDSYLL027
• Status: Recruiting
• Phase: N/A
• First received: June 7, 2017
• Last updated: June 9, 2017
• Start date: June 2017
• Est. completion date: October 2018

Study information

• Verified date: June 2017
• Source: Zhongda Hospital
• Contact: Chao Wang, Ph.D
• Phone: +86 151 9585 3100
• Email: wangchaoseu[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Dysphagia is the major symptom of patients with malignant esophageal stricture caused predominantly by advanced esophageal cancer. Stent placement is the most commonly used strategies for relieving the dysphagia and a novel irradiation stent loaded with 125I seeds has recently been developed. A multicentre randomized clinical trial demonstrated this irradiation stent can relieve the dysphagia rapidly and prolong the survival of patients with advanced esophageal cancer, but the total stent stenosis rate cannot be ruduced. A novel fully covered segmented retrievable irradiation stent was developed in our institute. The purpose of this study is to evaluate the safety and clinical efficacy of this newly developed irradiation stent in patients with unresectable malignant dysphagia.

Description:

Esophageal cancer is the eighth most common cancer and the sixth leading cause of cancer related mortality worldwide. Most patients have lost chance of surgical resection when they are initially diagnosed, because of late stage cancer or metastasis. Dysphagia is the major symptom of patients with advanced esophageal cancer. The two most commonly used strategies for relieving the dysphagia are stent placement and intraluminal brachytherapy. Stent placement provides a fast improvement of dysphagia, while intraluminal brachytherapy provides a more durable effect on dysphagia. To combine the advantages of the immediate relief of esophageal dysphagia with stent placement and long-term benefit with brachytherapy, a novel irradiation stent loaded with 125I seeds has been developed in the authors' institute. Recently, a multicentre randomized clinical trial demonstrated this novel irradiation stent can relieve the dysphagia rapidly and prolong the survival of patients with advanced esophageal cancer. However, this irradiation stent only provides a slightly longer relief of dysphagia and cannot reduce the total stent stenosis rate, because partly covered stent with uncoated flanges on both ends for anchoring the stent are used. In the past few years, fully covered retrievable stents which allow less tissue overgrowth have been used in patients with longer life expectancy, especially if they are receiving additional palliative therapy like brachytherapy. In order to provide a further longer relief of dysphagia and prevent stent migration caused by tumor regresses with brachytherapy, a fully covered segmented retrievable irradiation stent has been developed. The aim of the current study is to evaluate the clinical efficacy, particularly focus on stent stenosis and stent migration, and safety of this newly developed irradiation stent in patients with unresectable malignant dysphagia.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 38
• Est. completion date: October 2018
• Est. primary completion date: October 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 90 Years

Eligibility

Inclusion Criteria:

• Endoscopically and histologically confirmed malignant obstruction of the esophagus or the gastroesophageal junction

• Progressive dysphagia with a dysphagia score of 2-4

• Unresectable tumours due to extensive lesions, metastases, or poor medical condition

• Patients with clear consciousness, cooperation

• Eastern Cooperative Oncology Group (ECOG) performance status score of 0-3

• Informed consent: authorization and signature

Exclusion Criteria:

• The superior border of the lesion extending beyond the level of the seventh cervical vertebrae

• Previous treatment with a stent or surgical resection for the same condition

• Ulcerative esophageal cancer

• Esophageal fistula

• Severe hepatic inadequacy or renal inadequacy

Related Conditions & MeSH terms

• Deglutition Disorders
• Malignant Dysphagia

Intervention

Device:
• Fully covered irradiation stent
A esophageal fully covered segmented irradiation stent loaded with 125I seeds is placed in Patients with malignant dysphagia

Locations

Country	Name	City	State
China	Zhongda Hospital,Southeast University	Nanjing	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Zhongda Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Recurrent dysphagia	The rate of occurrence of tissue ingrowth or overgrowth, stent migration, and food obstruction.	Participants will be followed till die or lost to follow-up, an expected average of 6 months.
Secondary	Dysphagia score	Investigated with the Ogilvie score: 0 for nil, 1 for normal diet avoiding certain foods such as raw apple and steak, 2 for semi-solid diet, 3 for fluids only, and 4 for complete dysphagia, even for liquids.	Baseline, post-op 7 days, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months
Secondary	ECOG performance status	Utilizing ECOG performance status score to assess the functional status.	Baseline, post-op 7 days, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months
Secondary	EORTC QLQ-C30	Utilizing EORTC QLQ-C30 to assess the health-related quility of life.	Baseline, post-op 7 days, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months
Secondary	EORTC QLQ-OG25	Utilizing EORTC QLQ-OG25 to assess the health-related quility of life in patients with cancer of the oesophagus and the oesophago-gastric junction.	Baseline, post-op 7 days, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months
Secondary	Technical success	The rate of adequate placement of the stent in the target position and good passage of contrast medium through the stent into the stomach.	During operation
Secondary	Clinical success	The rate of relief of dysphagia with a decrease of at least one point in the dysphagia score.	3 days after stent placement
Secondary	Overall survival	Time from initial stenting to the day when the patients died or lost to follow-up.	Participants will be followed till die or lost to follow-up, an expected average of 6 months.
Secondary	Stent patency	Time from initial stenting to the day when recurrent dysphagia occured or patients died.	Participants will be followed till die or lost to follow-up, an expected average of 6 months.
Secondary	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	Adverse events including hemorrhage, perforation, fistula, severe chest pain, and pneumonia.	Participants will be followed till die or lost to follow-up, an expected average of 6 months.